美国BIND Therapeutics  
 BIND的生物科技是一家生物制药公司，开发治疗深刻改善集中在靶组织的药物，同时尽量减少系统性风险患者的生活能有针对性的纳米粒子。我们的技术平台，提供了独特的能力，为他们的特定应用优化治疗精确，重复性纳米我们。
　BIND公司制药科学副总裁杰夫·哈凯基表示，这是首个进入临床实践的可递送化疗药物的靶向型纳米粒子。接下来，公司会将其发展成一个平台，用于治疗心血管疾病、各类炎症，甚至传染性疾病。


BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate resistant prostate cancer.